Kosin Medical Journal

Case report

Interpedicular approach in percutaneous sacroplasty for treating pain due to direct invasion of rectal cancer into the S3 body: a case report: Jinseok Yeo, Saeyoung Kim, Chang Sub Lee; Received November 14, 2023 Accepted January 7, 2024 Published online February 20, 2024; DOI: https://doi.org/10.7180/kmj.23.153 [Epub ahead of print]

127 View
3 Download

Abstract PDF PubReader ePub: Percutaneous sacroplasty is mainly used as an intervention for pain associated with sacral insufficiency fractures or sacral metastatic tumors. However, sacroplasty for managing the pain associated with direct sacral invasion of rectal cancer has been rarely reported. We present a case of a 74-year-old patient who underwent sacroplasty via the interpedicular approach under fluoroscopic guidance to relieve pain resulting from direct tumor invasion into the S3 body. After the procedure, the patient experienced immediate pain relief and did not feel worse pain with ambulation. Aside from peritumoral vascular leakage, no other significant complications occurred immediately post-procedure. Our results suggest that fluoroscopically guided interpedicular sacroplasty is a safe and effective option for relieving the pain associated with direct sacral invasion by rectal cancer.

Original article

The effects of ketamine on pain control in stage IV cancer patients receiving palliative care: Seonghoon Kim, Jihun Kang, Jongsoon Choi, Eunhee Kong; Kosin Med J. 2022;37(1):37-45. Published online March 14, 2022; DOI: https://doi.org/10.7180/kmj.21.003

2,360 View
69 Download
2 Citations

Background
We evaluated the effects of intravenous ketamine on cancer pain in stage IV cancer patients receiving palliative care.
Methods
In total, 253 stage IV cancer patients with cancer pain hospitalized at a single tertiary hospital palliative care unit were included. The ketamine group contained 112 patients receiving ketamine, and the control group comprised 141 non-ketamine users. To evaluate the odds ratios (ORs) for favorable pain control, optimal pain control, and opioid-sparing effect among ketamine users, we used multivariable logistic regression adjusted for age and objective prognosis score. Differences in the visual analog scale (VAS) score, oral morphine equivalents, inter-dose frequency, and inter-dose amount were compared between both groups at the time of ketamine introduction (T0), after 24 hours (T1), and after 48 hours (T2) using repeated-measures analysis of covariance.
Results
The ketamine group was more likely to show favorable pain control (OR, 3.84; 95% confidence interval [CI], 1.76–8.37) and an optimal response (OR, 3.99; 95% CI, 1.73–9.22) than the control group. Compared to the control group, the ketamine group showed a higher VAS score at T0, but a more evident VAS score reduction at T1 and T2 (pint<0.001). The ketamine group was less likely than the control group to experience depressive mood (OR, 0.31; 95% CI, 0.10–0.92), but had a higher risk of delirium (OR, 2.06; 95% CI, 1.12–3.91).
Conclusion
Our findings suggest that ketamine can effectively reduce refractory cancer pain in stage IV cancer patients.

Citations

Citations to this article as recorded by

Prevalence of Pain and Factors Affecting it in Patients with Lung Cancer in Ilam
Elham Bastani, Mahsa Rizehbandi, Fariba Shokri
International Journal of Cancer Management.2024;[Epub] CrossRef
Is ketamine useful for pain management in patients with stage IV cancer?
Sung Eun Kim
Kosin Medical Journal.2022; 37(1): 1. CrossRef

Review article

Psychiatric Aspects of Cancer Pain: Ho Chan Kim; Kosin Med J. 2009;24(1):7-13. Published online June 30, 2009

187 View
1 Download

PDF

First
Prev
Page of 1
Next
Last

Search